Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Long-Term Debt Issuances (2020)

Theravance Biopharma (TBPH) has disclosed Long-Term Debt Issuances for 1 consecutive years, with $380.0 million as the latest value for Q1 2020.

  • Quarterly Long-Term Debt Issuances changed N/A to $380.0 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $380.0 million through Dec 2020, changed N/A year-over-year, with the annual reading at $380.0 million for FY2020, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q1 2020 was $380.0 million at Theravance Biopharma.
  • The five-year high for Long-Term Debt Issuances was $380.0 million in Q1 2020, with the low at $380.0 million in Q1 2020.